This report describes the global market size of microneedle drug delivery systems market from 2018 to 2021 and its CAGR from 2018 to 2021, and also forecasts its market size to the end of 2030 and it is expected to grow with a CAGR of 7.6% from 2023 to 2030.
Microneedles are a type of transdermal drug delivery system that does not cause discomfort, is not as intrusive as other methods, is simple to use for self-administration, and has a high drug bioavailability. Due to safer alternatives to conventional hypodermic injection, which is minimally invasive and allows for painless administration, there is a rising need for microneedle drug delivery devices. Additionally, the industry demand is being driven by the rising incidence of diabetes. Additionally, the market is expanding due to the use of smart devices and technological advancements like AI and data analytics.
Due to the COVID-19 pandemic and Russia-Ukraine war influence, the global market for microneedle drug delivery systems market estimated at US $ million in the year 2022, is projected to reach a revised size of US$ million by 2030, growing at a CAGR of 7.6% during the forecast period 2023-2030. North American market for Microneedle Drug Delivery Systems Market is estimated to increase from $million in 2022 to reach $ million by 2030, at a CAGR of XX% during the forecast period of 2023 through 2030.
For geography segment, regional supply, demand, major players, price is presented from 2018 to 2030. This report covers following regions:
Middle East and Africa
The key countries for each region are also included such as United States, China, Japan, India, Korea, Germany, France, UK, Italy, Spain, and Brazil etc.
For competitor segment, the report includes global key players of Microneedle Drug Delivery Systems Market as well as some small players. The information for each competitor includes:
Main Business Information
Sales Volume, Revenue, Price and Gross Margin
Hollow microneedles generated over 26% of sales in 2022. Insulin for diabetics is delivered via hollow microneedles. These microneedles are ideal for vaccination and hormone therapy patients because they can hold more medicine.
It also delivers medications and vaccines painlessly by not activating nerve ends. In 2021, 8.5% of adults (20-79) had type 2 diabetes, affecting 537 million people worldwide, according to the International Diabetes Federation (IDF).
Dissolving microneedle segment is expected to grow at the fastest rate during the forecast period. The dissolving microneedle delivers active chemicals in one step without removal, making it less unpleasant than the syringe. Patients who need frequent injections may benefit from this.
Dissolving biodegradable microneedles allow drug administration without leaving sharp, bio-contaminated, and non-degradable debris. These factors should boost market growth.
In 2022, metal material revenue topped 28%. Titanium and stainless steel are used most. Nickel and palladium-cobalt alloys are also used. They're strong and biocompatible. Metals are stronger than silicon, therefore they make superior microneedles. Microneedles were first made of stainless steel. Thus, these factors should boost segment growth.
Silicone material is projected to have the highest CAGR. Its elasticity allows it to make needles of various sizes and shapes. Its pleasant properties make it adaptable. The FDA cleared silicon devices, including NanoPass Technologies Ltd.'s silicon microneedles, which may increase market growth.
Drug delivery has 35% market share in 2022. Insulin is peptide-based. Cancer, diabetes, and cardiovascular disorders are major contributors to this rise. The global burden of chronic diseases is rising, necessitating more precise and effective drug delivery technologies.
Medication discovery breakthroughs have also boosted medication delivery expansion. New drugs have complex targets and low bioavailability. Innovative medicine delivery systems that maximise efficacy and minimise negative effects have resulted.
Cancer therapy is anticipated to rise at 8.3% CAGR. Governments are funding more cancer research and therapy as cancer rates rise worldwide. In 2020, cancer killed approximately one in six people worldwide. Targeted, immuno, and gene therapies have also emerged from cancer research. These cancer treatments have better results and fewer adverse effects than standard chemotherapy, increasing demand.
Middle East & Africa
North America had 44% of market revenue in 2022. Microneedle drug delivery is driven by the region's robust pharmaceutical industry. Leading pharmaceutical companies in the region are developing microneedle-based drug delivery systems, propelling market expansion.
The regulatory environment also supports microneedle-based medication delivery devices. Microneedle technology has seen greater investment and innovation due to FDA and Health Canada backing.
Microneedle medication delivery systems are expected to grow 8.2% in Asia Pacific. Healthcare spending has increased, spurring microneedle medication delivery research and development. This has helped produce new and innovative products and technologies, boosting market growth.
In 2021, India launched the Digital Health Mission to create a unified digital health infrastructure. Telemedicine, e-pharmacies, and electronic health records will be possible.
Novartis International AG
Becton Dickinson and Company
Nanopass technologies limited
Mitsubishi Chemical Holdings Corporation.
Siemens Healthineers AG
Please ask for sample pages for full companies list
Base Year: 2022
Historical Data: from 2018 to 2021
Forecast Data: from 2023 to 2030
Any special requirements about this report, please let us know and we can provide custom report.